Aura Biosciences (AURA) Q3 2026 earnings review
Aura Biosciences finishes Phase 3 dosing, while layoff costs top plans
Aura Biosciences finished dosing patients in its main eye-cancer trial while completing a summer staff cut. Operating expenses rose 26% from a year ago to $35 million, or 10% excluding $4.5 million in layoff charges by our math, as quarterly spending dropped from the second quarter. Chief executive Natalie Holles kept the target for pivotal trial results in the second half of 2027 and signed a manufacturing partner for commercial supply.
| Operating expenses | $35.1M +25.6% from a year ago (-27.1% from Q2) |
|---|---|
| Operating expenses, excluding one-offs | $30.6M +9.5% from a year ago by our math |
| Cash and marketable securities | $297.2M $323.8M last quarter |
| Cash runway outlook | Unchanged funds operations into 1H 2029 |
⚖️ Verdict: 🟢 Bullish
The story got better because every patient in the 108-person Phase 3 trial has now completed treatment visits, removing dosing delays ahead of next year's readout. One caution: the workforce restructuring cost $4.5 million, nearly half again what the company planned three months ago, and underlying overhead did not shrink from a year ago.
The question now is whether quarterly cash usage stays below the $27 million average needed to reach mid-2029 once commercial manufacturing work ramps up. If factory preparation costs stay low, existing cash easily covers the business past the 2027 readout; if production setup bills climb, the cushion tightens. Fourth-quarter operating expenses, the first clean period after the layoffs, will show the true baseline burn.
🐂 Bull Case
All Phase 3 Patients Finished Dosing
Aura Biosciences develops bel-sar, an experimental light-activated drug for early choroidal melanoma, which it describes as "the most common primary tumor of the eye which carries an approximately 50% risk of advancing to metastatic disease". Chief executive Natalie Holles said all 108 patients in the Phase 3 CoMpass study have now finished their treatment visits and are "in the 24-month follow-up observation period".
Finishing the injections removes the risk of treatment delays, because every patient is now ticking toward the 15-month primary checkup. The biotech firm runs the study under a Special Protocol Assessment (SPA), a written agreement with US regulators on how the trial is designed and measured, and keeps its target for initial results in the second half of 2027.
What to watch: the virtual investor event on December 8, 2026. Management and an outside eye specialist will present an updated analysis of patient numbers for early choroidal melanoma, showing the commercial reach if the trial succeeds.
Research Spending Slowed After Dosing Ended
Aura spent $24.7 million on research and development this quarter, up 11.6% from a year ago due to "ongoing clinical and contract research organization (CRO) costs associated with the progression of the global Phase 3 CoMpass trial". However, research spending dropped 19.5% from the second quarter's $30.7 million as patient dosing wrapped up and the summer layoffs took effect.
That drop brought the quarterly cash usage down to $26.6 million by our math, from $323.8 million in cash and securities in June to $297.2 million in September. By our math, funding operations through the middle of 2029 allows an average spend of $27.0 million a quarter over 11 quarters, so current spending fits the budget.
What to watch: fourth-quarter operating expenses, the first full period without severance charges or Phase 3 dosing bills. A further drop in quarterly cash use would leave more money for commercial launch preparation in 2027.
Manufacturing Partner Adds Dedicated Supply
Preparing a drug for regulatory approval requires proving that a factory can make it consistently at commercial scale. This quarter the eye-cancer developer signed a supply agreement with a contract development and manufacturing organization (CDMO), an outside drug manufacturer with "extensive commercial experience in the manufacture of viral vector-based medicinal products".
Operating chief Susan Abu-Absi said "Designated capacity is intended to provide us with long-term control over our production scheduling". Securing a dedicated production line ahead of the 2027 trial readout reduces the risk that manufacturing bottlenecks delay a license application to US regulators.
What to watch: future research and development expenses for manufacturing setup fees. Rising factory reservation costs could push quarterly spending back above the $27.0 million average needed to reach mid-2029.
🐻 Bear Case
Layoffs Cost Half Again the Initial Plan
In the second quarter, Aura cut about a fifth of its staff to "align resources behind its ocular oncology portfolio" and projected total restructuring charges of $2.9 million to $3.2 million for 2026. This quarter the company completed the layoffs but booked $4.5 million in severance, health benefits and accelerated stock awards, 47.5% above the middle of its own plan by our math.
Those exit packages pushed general and administrative expenses (overhead and management pay) up 80.2% from a year ago to $10.3 million, lifting total operating expenses 25.6% to $35.1 million. Excluding the $4.5 million charge, overhead was $5.8 million by our math, up 1.6% from $5.7 million a year ago rather than shrinking after the departures.
What to watch: general and administrative spending in the fourth quarter. If overhead stays near $5.8 million despite a smaller staff, the restructuring will have failed to lower baseline administrative costs.
Earlier Eye Cancer Trials Still Lack Dates
Beyond its main trial, Aura is testing bel-sar in cancers that have spread to the eye (metastases to the choroid) and tumors on the outer surface of the eye. Earlier this year the company planned to report initial clinical results from both studies during 2026, before pushing the update to the first quarter of 2027.
- Early choroidal melanoma addressable patients: about 11,000 a year in the US and Europe
- Metastases to the choroid addressable patients: about 20,000 a year
- Ocular surface cancers addressable patients: about 35,000 a year
The two follow-on eye indications represent 55,000 patients a year, five times the size of the primary program, while the previously deprioritized bladder cancer trial disappeared from this quarter's release entirely. Until Aura shares clinical data from the secondary eye studies, the entire business rests on the single 108-patient CoMpass readout.
What to watch: the promised first-quarter 2027 program update. Investors need concrete patient counts and data readout dates rather than just trial design descriptions.
👓 Other Themes
Share Offerings Cut Per-Share Loss
Aura's net loss widened 22.7% from a year ago to $32.1 million, but its net loss per share shrank 27.5% from $0.40 to $0.29. Weighted average shares jumped 68.5% to 111.1 million after the May 2026 stock offering raised $280.8 million and funded a $39.1 million share buyback from Matrix Capital, spreading the larger loss across many more shares.
💲 Other KPIs
Cash and marketable securities rose 83.6% from $161.9 million a year ago after the May stock offering, but fell $26.6 million from $323.8 million in the second quarter. The drug developer carries no debt and expects this reserve to fund operations into the first half of 2029.
Interest earned on cash reserves jumped 66.2% from $1.8 million a year ago and rose from $2.3 million in the second quarter. The larger cash balance after the May financing generated enough interest to offset two-thirds of this quarter's $4.5 million restructuring charge.
Accrued expenses — bills the company has recorded for clinical trials and employee benefits but not yet paid in cash — grew 19.9% from $13.6 million at the end of 2025 and rose from $14.0 million in June. Paying down these unpaid bills will draw on cash in coming quarters.
🔮 Guidance
Unchanged. Aura still expects its $297.2 million in cash and securities to fund operations into the first half of 2029. By our math, that leaves an average quarterly cash burn of about $27.0 million across the next 11 quarters, matching the $26.6 million used in the third quarter.
Unchanged. The clinical-stage group still expects 15-month primary results from its 108-patient eye cancer trial in the second half of 2027. With all patient treatment visits now complete, the timeline depends entirely on the fixed 15-month observation clock.
Unchanged. Management kept its plan to share details on disease burden, trial design and future readout timelines for both earlier-stage eye cancer studies in the first quarter of 2027, after shifting the target from 2026 last quarter.
❓ Key Questions
Why did layoffs cost 48% more than planned?
Aura projected $2.9 million to $3.2 million in restructuring charges three months ago but booked $4.5 million this quarter. Investors need to know whether extra employees left or severance packages were enlarged.
Will the Q1 2027 update include clinical patient data?
The release promises details on disease burden, trial design and timelines for the two earlier-stage eye trials in the first quarter of 2027, without mentioning efficacy results once planned for 2026.
What are the financial commitments for the new factory line?
Aura secured dedicated production capacity with a contract manufacturer for bel-sar. Management has not disclosed the minimum purchase obligations or setup fees tied to that reservation.
Has data collection finished for the bladder cancer study?
Last quarter Aura deprioritized its bladder cancer program but said it would finish collecting data from the current study. The third-quarter release did not mention bladder cancer at all.